EYPT Quote, Financials, Valuation and Earnings

Ocular Therapeutix, Inc. has a net margin of -6183.44% compared to EyePoint Plc's net margin of -487.96%. EyePoint Plc's return on equity of -79.15% beat Ocular Therapeutix, Inc.'s return on equity of -73.88%.

EyePoint Plc has a consensus price target of $36.08, signalling upside risk potential of 135.38%. On the other hand Ocular Therapeutix, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 229.91%. Given that Ocular Therapeutix, Inc. has higher upside potential than EyePoint Plc, analysts believe Ocular Therapeutix, Inc. is more attractive than EyePoint Plc.

EyePoint Plc has a beta of 1.758, which suggesting that the stock is 75.759% more volatile than S&P 500. In comparison Ocular Therapeutix, Inc. has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.856%.

EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Plc pays -- of its earnings as a dividend. Ocular Therapeutix, Inc. pays out -- of its earnings as a dividend.

EyePoint Plc quarterly revenues are $966K, which are smaller than Ocular Therapeutix, Inc. quarterly revenues of $13.3M. EyePoint Plc's net income of -$59.7M is higher than Ocular Therapeutix, Inc.'s net income of -$64.7M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Ocular Therapeutix, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 24.84x versus 28.04x for Ocular Therapeutix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -6183.44% compared to EyePoint Plc's net margin of 21.74%. EyePoint Plc's return on equity of -79.15% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

EyePoint Plc has a consensus price target of $36.08, signalling upside risk potential of 135.38%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $869.96 which suggests that it could grow by 11.58%. Given that EyePoint Plc has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe EyePoint Plc is more attractive than Regeneron Pharmaceuticals, Inc..

EyePoint Plc has a beta of 1.758, which suggesting that the stock is 75.759% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.94 per share. EyePoint Plc pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

EyePoint Plc quarterly revenues are $966K, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. EyePoint Plc's net income of -$59.7M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 24.84x versus 5.90x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tango Therapeutics, Inc. has a net margin of -6183.44% compared to EyePoint Plc's net margin of 29.52%. EyePoint Plc's return on equity of -79.15% beat Tango Therapeutics, Inc.'s return on equity of -56.44%.

EyePoint Plc has a consensus price target of $36.08, signalling upside risk potential of 135.38%. On the other hand Tango Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 25%. Given that EyePoint Plc has higher upside potential than Tango Therapeutics, Inc., analysts believe EyePoint Plc is more attractive than Tango Therapeutics, Inc..

EyePoint Plc has a beta of 1.758, which suggesting that the stock is 75.759% more volatile than S&P 500. In comparison Tango Therapeutics, Inc. has a beta of 1.750, suggesting its more volatile than the S&P 500 by 75.038%.

EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tango Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Plc pays -- of its earnings as a dividend. Tango Therapeutics, Inc. pays out -- of its earnings as a dividend.

EyePoint Plc quarterly revenues are $966K, which are smaller than Tango Therapeutics, Inc. quarterly revenues of $53.8M. EyePoint Plc's net income of -$59.7M is lower than Tango Therapeutics, Inc.'s net income of $15.9M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Tango Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 24.84x versus 20.20x for Tango Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -6183.44% compared to EyePoint Plc's net margin of --. EyePoint Plc's return on equity of -79.15% beat Viking Therapeutics, Inc.'s return on equity of -46.41%.

EyePoint Plc has a consensus price target of $36.08, signalling upside risk potential of 135.38%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $92.72 which suggests that it could grow by 198.82%. Given that Viking Therapeutics, Inc. has higher upside potential than EyePoint Plc, analysts believe Viking Therapeutics, Inc. is more attractive than EyePoint Plc.

EyePoint Plc has a beta of 1.758, which suggesting that the stock is 75.759% more volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.489%.

EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Plc pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

EyePoint Plc quarterly revenues are $966K, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. EyePoint Plc's net income of -$59.7M is higher than Viking Therapeutics, Inc.'s net income of -$157.7M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 24.84x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.